Skip to content

Shares (Diluted) at other companies

Eli Lilly logo
Eli LillyLLY
895.9M-0.5%
Amgen logo
AmgenAMGN
544M+0.6%
Incyte logo
IncyteINCY
206.8M+4.4%
AbbVie logo
AbbVieABBV
1.8B+0.1%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
78.5M+30.3%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE

Other financials

Income statement

See full
Revenue$56.4M+99.0%
Operating income-$3.6M+81.1%
Net income$3.8M+132%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$193.7M+38.7%
Total debt$9.8M-13.9%
Total equity$655.5M-4.9%
Total assets$697.5M-6.0%

Cash flow

See full
Operating cash flow-$48.9M-139%
CapEx$215.0K-60.6%
Free cash flow-$49.2M-139%

Valuation

See full
Market cap$7.26B+127%
Enterprise value$7.07B+130%
P/S98×+82.6×

Profitability

See full
Operating margin-192.4%-205pp
Net margin-154.9%-182pp
FCF margin-12,264.3%-12,527pp

Returns & leverage

See full
Return on equity-17.1%-26.1pp
Debt / equity0.0×
Current ratio17.8×+0.5×

Where this comes from

Reported directly by Protagonist Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Protagonist Therapeutics's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Protagonist Therapeutics's shares (diluted)?
Protagonist Therapeutics (PTGX) reported shares (diluted) of 70.5M in Q1 2026.
How has Protagonist Therapeutics's shares (diluted) changed year-over-year?
Protagonist Therapeutics's shares (diluted) increased by 12.0% year-over-year, from 63M to 70.5M.
What is the long-term trend for Protagonist Therapeutics's shares (diluted)?
Over 4 years (2021 to 2025), Protagonist Therapeutics's shares (diluted) has grown at a 8.5% compound annual growth rate (CAGR), from 183.4M to 253.8M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.